1296201-68-7

Basic information

• Product Name: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester
• Synonyms: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester;ethyl 7-chloroiMidazo[1,2-a]pyridine-3-carboxylate;7-Chloro-iMidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester
• CAS NO: 1296201-68-7
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.64366
• Mol File: 1296201-68-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester(1296201-68-7)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester(1296201-68-7)

Safety Data

• Hazardous Substances Data: 1296201-68-7(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, ethyl ester is a chemical compound with the molecular formula C11H9ClN2O2. It is an ethyl ester derivative of imidazo[1,2-a]pyridine-3-carboxylic acid, 7-chloro-, which is a heterocyclic compound and an important intermediate in the synthesis of pharmaceuticals and agrochemicals. The addition of an ethyl ester group enhances the compound's solubility and stability, making it suitable for use in various chemical processes and applications. It is commonly used in the pharmaceutical industry for the synthesis of drug candidates and in the development of new active pharmaceutical ingredients. Additionally, it has potential applications in the field of agrochemicals for the development of new pesticides and herbicides.

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 1027194-45-1 potassium (1E)-2-chioro-3-ethoxy-3-oxoprop-1-en-1-olate 
• 1072-98-6 5-chloro-2-pyridylamine 
• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 

Downstream Products

• 1019022-33-3 7-chloro-imidazo[1,2-a]pyridine-3-carboxylic acid 

Relevant articles and documents

Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy

A diverse series of 1,2,4-oxadiazoles based substituted compounds were designed, synthesized and evaluated as anticancer agents targeting carbonic anhydrase IX (CAIX). Initial structure-activity analysis suggested that the thiazole/thiophene-sulfonamide conjugates of 1,2,4-oxadiazoles exhibited potent anticancer activities with low μM potencies. Compound OX12 exhibited antiproliferative activity (IC50 = 11.1 μM) along with appreciable inhibition potential for tumor-associated CAIX (IC50 = 4.23 μM) isoform. Therefore, OX12 was structurally optimized and its SAR oriented derivatives (OX17-27) were synthesized and evaluated. This iteration resulted in compound OX27 with an almost two-fold increase in antiproliferative effect (IC50 = 6.0 μM) comparable to the clinical drug doxorubicin and significantly higher potency against CAIX (IC50 = 0.74 μM). Additionally, OX27 treatment decreases the expression of CAIX, induces apoptosis and ROS production, inhibited colony formation and migration of colon cancer cells. Our studies provide preclinical rational for the further optimization of identified OX27 as a suitable lead for the possible treatment of CRC.

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.